Introduction
Gliomas are the most frequently occurring primary brain tumors in humans, and can be subdivided into three histological subtypes, that is, astrocytoma, oligodendroglioma and mixed oligoastrocytoma (OA), each characterized by a different grade of malignancy according to the WHO classification (Kleihues and Cavenee, 2000) . Despite recent technical improvements in radiological and pathological diagnostic procedures, as well as the increasing knowledge on glioma biology and genetics, the possibilities for effective treatment and prognosis remain poor, especially for patients affected by glioblastoma (GBM) (the most aggressive astrocytic form), who have an average survival of o1 year after diagnosis (Simpson et al., 1993) . At the other side of the prognostic spectrum, oligodendroglial tumors exhibiting loss of chromosomal arms 1p and/or 19q show a better response to chemotherapy and, consequently, a better prognosis (Cairncross et al., 1998; Ino et al., 2001; Jeuken et al., 2004) .
Difficulties in clinical management (e.g. treatment and prognosis) are related to the complex identity of gliomas, which impairs a clearcut classification needed for discrimination between different tumor subtypes. Limitations of the actual diagnostic criteria are pointed out by data on both the different combinations of genetic lesions in tumors sharing similar histology, grade and intratumor genetic heterogeneity (Noble and Dietrich, 2004) . For these reasons, there is a growing awareness that genome-wide and high-resolution genetic analyses will contribute to the improvement of the current WHO classification by constructing a more objective molecular taxonomy of gliomas (Mischel et al., 2004) .
For this purpose, over the last decade molecular approaches including mutation screening, comparative genomic hybridization (CGH) and loss of heterozygosity (LOH) analyses have led to the identification of the most frequently recurring genomic imbalances correlating to each WHO subtype (Koschny et al., 2002; Shapiro, 2002; Kitange et al., 2003) and to the identification of several genes acting in pathways involved in glioma development, either in the initiation stages (p53 and Ras by PDGF-NF1) or in malignant progression (Rb-CDKN2-CDK4) (Zhu and Parada, 2002; Collins, 2004) . Deletion of 19q is of particular interest, as it is shared by all three glioma subtypes, occurring in approximately 75% of oligodendroglioma, 45% of mixed OA and 40% of astrocytoma (von Deimling et al., 1992 (von Deimling et al., , 1994 , where it is associated with the transition from low-grade to anaplasic tumors (Ohgaki et al., 1995; Ritland et al., 1995; Smith et al., 1999) . Furthermore, similarly to oligodendroglioma, combined LOH of 1p and 19q was found to define a small subset of GBM patients with a significantly better survival, even if their tumors are not morphologically distinguishable from the bulk of GBMs (Schmidt et al., 2002) .
A candidate tumor suppressor region has been assigned by LOH studies to 19q13.3, but no prime positional functional candidate gene in this band has yet been identified (Hartmann et al., 2002) . We postulated a possible role for the novel serine threonine kinase gene MARK4, which maps at the centromeric boundary of the 19q13.3 LOH region, and which is overexpressed and duplicated in three GBM cell lines (Beghini et al., 2003) .
In order to improve our current knowledge on both gross and subtle genetic changes involved in glioma initiation and progression, we interrogated 25 primary cell lines at the whole genome level by array-based comparative genomic hybridization (array-CGH or aCGH) at a 1 Mb resolution. Since chromosome 19 is of particular interest in the context of clinical decisionmaking, a full genomic chromosome 19 tiling path was also present on our arrays (our current resolution on chromosome 19 is in theory around 50 kb, and in practice around 100 kb).
Few high-resolution aCHG studies on gliomas are currently available to complement previously published CGH, SKY and LOH analyses (Cowell et al., 2004a, b; Bredel et al., 2005; Kitange et al., 2005; Nigro et al., 2005) , which have all demonstrated an excellent correlation between the findings obtained through this approach, and those obtained by alternative techniques, stressing the usefulness and overall accuracy of this genomic approach as compared to classic most widely employed analyses (Cowell et al., 2004a, b) .
Comparative analysis of elaborated aCGH data obtained on our cell lines collection allowed us to identify copy number changes shared by various glioma grades as well as aberrations apparently related to progression to GBM. Besides the confirmatory copy number alterations previously identified in gliomas, we also identified several genomic intervals containing novel candidate genes involved in gliomagenesis and/ or progression recurrently found to be affected. Further clinical validation of these intervals by dedicated approaches might enable their inclusion among the genetic markers useful for a prognostic classification of gliomas, and is expected to ultimately lead to improved clinical decision-making.
Results

Recurrent genomic imbalances
Aiming at the detection of recurrent genomic copy number changes involved in glioma genesis and/or progression, we characterized 15 grade I-III gliomas (defined as 'non-GBMs') and 10 GBMs primary cell lines (Supplementary Table A) by aCGH on a 3.5k whole genome plus full-coverage chromosome 19 BAC array. Figure 1 depicts all the autosome ideograms (except chromosome 19, which is shown separately and in more detail in Figure 3 ) with the corresponding copy number changes identified in each cell line by the combined application of two statistical approaches: the whole chromosome association analysis and the 'moving average (MA)' algorithm. Whole chromosome association analysis defines entirely gained or lost chromosomes (Hackett et al., 2003) , whereas the 'MA algorithm' allowed us to cluster gained or lost clones with aberrant average ratios in consecutive areas of copy number changes (Schraders et al., 2005) . For more defined regions affecting at least four cases of partial chromosomal arm imbalance, the smallest regions of overlap (SROs), defined as the minimal regions of deletion/gain overlap, were also determined as shown in Table 1 , where detailed clone information as well as the physical location (Mb positions) of the encompassing and flanking clones is also provided. Figure 1 and Table 1 show genomic imbalance affecting either specifically GBMs or non-GBMs or, alternatively, both. The most frequent changes exclusive for GBMs involve complete or partial gain of chromosome 7 (70%), loss of chromosomes 10 (100%) and 22 (40%) (Kitange et al., 2003) , which are known to be involved in glioma progression, as well as gain at 1q32 (Riemenschneider et al., 2003) , detected in three GBMs and in one non-GBM. We also identified novel recurrent findings unreported in previous studies. We found that only GBMs show loss of chromosome 18 (40%) and gain of the entire chromosome 21 (50%). Double I-FISH using two chromosome 21 BACs lying B7 Mb apart from each other confirmed the aCGH gain in showing a very high number (>8) of signals for both probes in the great majority of nuclei of the representative MI-7 cell line (chromosome 21 average log 2 ratio ¼ þ 0.3) (see Supplementary Figure A) .
A small overlapping region mapping at 4p16.1 is also specifically lost in four (40%) GBM cell lines. Array-based CGH in glioma cell lines G Roversi et al Three SROs mapping at 3p26, 4q13-21 and 7p15-21 turn out to be exclusively lost in, respectively, eight (53%), five (33%) and four (26%) of non-GBMs, whereas both glioma groups share partial losses at 4p15, 5q, 6p and 12 p and gains at 11p-q (Table 1) .
In addition, the use of the 'MA' algorithm allowed us to estimate which areas are quantitatively more involved within entirely gained or lost chromosomes such as chromosomes 10 and 7, the two most frequent aberrations found in gliomas. As depicted in Figure 1 , seven GBM cell lines showed loss of the entire chromosome 10. As shown in Figure 2 , three distinct areas emerged in all cell lines by using this algorithm. The three areas on chromosome 10 encompass several candidate tumor suppressor genes, including KLF6, LGI1, PTEN, DMBT1, WDR11 and MXI1, already known to be indeed associated with glioma progression (Chernova et al., 2001; Manni et al., 2002; Kohler et al., 2004) . One region spans from 10pter to 10p14, with a peak between clones RP11-89B19 and RP11-80D10 at 10p15.3 telomerically to KLF6; only the ADARB2 gene, a brain-specific adenosine deaminase, resides within this interval. The second interval, mapping at 10q22.2-10q23.33, shows a peak of loss at 10q22.3, centromerically to PTEN between clones RP11-45P20 and RP11-342M3 and includes five annotated genes. The third region, spanning 10q25-26, has a peak at 10q26.13-q26.2 between clones RP11-70E19 and RP11-32H11 and telomeric to DMBT1: the peak loss area comprises 12 fully assigned genes.
When chromosome 7 was tested by the same approach, a homogeneous trend of imbalance along the entire chromosome was revealed, and no recurrent areas with significant deviation from whole chromosome average could be detected (data not shown).
DNA copy number changes detected by the full chromosome 19 coverage subarray Motivated by the frequent involvement of chromosome 19q in gliomas (von Deimling et al., 1992 (von Deimling et al., , 1994 Ohgaki et al., 1995; Ritland et al., 1995; Smith et al., 1999; Schmidt et al., 2002) and our recent data on the duplication of MARK4 in three GBM cell lines (Beghini et al., 2003) , we pursued a high-resolution characterization of chromosome 19 in our cell lines through the use of full genomic coverage aCGH for this particular chromosome.
By applying the 'MA' algorithm, two frequently gained regions of interest, mapping to 19p13.11 and 19q13.13-13.2, respectively, emerged, for each of which a SRO could be defined (Figure 3) . The 19p13.11 interval, with a SRO spanning about 350 kb (from RP11-365K12 to RP11-350I20) encompasses 13 genes and was gained in three non-GBM and four GBM cell lines. The 19q13.13-13.2 interval was gained in three non-GBM and four GBM cell lines too. This latter 630 kb interval (from RP11-1031M21 to RP11-452P05) contains 16 genes. Moreover, we were able to detect at 19p13.2 (8.55-8.81 Mb) a region of copy number changes (lost and gained) in 20 cell lines as well in three normal versus normal hybridizations. By further analysis, we could establish that copy number changes behaved in a 'hybridization reference-dependent' way (data not shown), confirming its polymorphic nature, consistent with the information on clone RP11-79F15 provided by the Genome Variation Database (http://projects.tcag. ca.variation) (Iafrate et al., 2004; Sebat et al., 2004) . In our normal controls, the largest polymorphic region spans 260 kb, and is located between clones RP11-92E05 and RP11-203K06. Array-based CGH in glioma cell lines G Roversi et al
By means of the 'MA' algorithm, we also found that the interval characterized by five overlapping clones, and containing the entire MARK4 gene, belongs to a region of gain in three non-GBM (MI-67, MI-26, G43) and one GBM (MI-4) cell lines. Moreover, a GBM cell line (MI-63) showed a gained region partially included in the MARK4 overlapping clones, while only one non-GBM cell line (MI-13, AOA) presented a deletion in the candidate tumor suppressor region 19q13.3 stretching to MARK4. The SRO gained region, placed at the centromeric boundary of LOH tumor suppressor area (Figure 3 ), is comprised between clones RP11-752G09 and CTD-2344L03, where, besides MARK4, the creatine kinase, CKM, kinesin light chain, KLC2, the DNA repair genes, ERCC1 and 2, the inhibitor of p53 function, PPP1R13L, and the nucleolar autoantigen gene, ASE-1, reside.
Single clone analysis A total of 29 homozygously deleted clones (log 2 ratiooÀ0.8) were identified in eight GBM cell lines (Table 2) , whereas grade I-III glioma cell lines did not reveal any homozygously deleted clones. In all, 14 clones mapping to 12p12.1-p13.32 belong to a rather large (B23 Mb) area of deletion in the G32 cell line and a few reside in the previously described 12p SRO (Table 1) . As the G32 cell line shows by aCGH the loss of the entire chromosome 12, in order to confirm that 12p13.1 (targeted by clone RP11-439G16, log 2 ratio À0.85) is under-represented as compared to 12q (monitored by clone RP11-141F8, log 2 ratio À0.25), we performed dual color I-FISH to evaluate the ratio between the number of signals given by the two clones. Scoring of 100 nuclei revealed that the ratio of 12q:12p copies as determined by aCGH (1.68:1.10 ¼ 1.52) underestimated the ratio obtained by FISH (1.95) (see Supplementary Figure B ). Only clone CTD-2154O24 mapping to chromosome 9p21 appeared to be deleted in more than one GBM cell line (MI-7 and MI-4) and contains the CDKN2A (p16) gene, a well-known tumor suppressor gene known to be involved in glioma progression (Zhu and Parada, 2002) . Chromosomes 10 and 22 show multiple regions of homozygous deletions. More specifically, clone RP11-129G17, which resides at 10q23 and flanks the PTEN gene, which is known to be of functional relevance in gliomas (Zhu and Parada, 2002; Rong et al., 2005) , is homozygously deleted. In addition, two clones mapping to 10q26.2, although not consecutive, probably delimit the same deletion in cell line MI-63, as two clones between them present log 2 ratio oÀ0.5. The observation of discontinuous intervals may be explained by ambiguous mapping positions, subject to change upon release of future, revised genome-builds. Indeed, most nuclei (92/100) of the MI-63 cell line did not show any hybridization signal following I-FISH with the RP11-32H11 clone labeled either by green or red fluorescence (see Supplementary Figure C) .
By comparing the frequencies of the most frequently heterozygously deleted clones (log 2 ratiooÀ0.3) among 15 non-GBMs and 10 GBMs (Table 3) , a picture Array-based CGH in glioma cell lines G Roversi et al emerges in which both glioma groups share high-frequency deletions for the clone RP11-709A23 at 12p11.23, whereas other clones are exclusively involved in one of the two histological subgroups. Among these, clones mapping to 3p26 and 4q13.3, which fall in the previously described SROs (a), stand out among nonGBMs, just as clones mapping at 12p13.1 (RP11-439G16 and RP11-1092P21), sorted also as homozygous deletions (c), emerge among GBMs.
We did not detect any clones with amplified signal intensities (log 2 ratio >1), whereas gained clones showing a log 2 ratio's between 0.5 and 1 (Table 4) were detected for 31 clones in I-III grade gliomas, and for 201 clones in GBMs. The majority maps to chromosome 7, belongs to cell lines with additional chromosome(s) 7 and is not involved in non-GBM cell lines, with the exception of RP5-953A4 at 7q11.23, which is gained in one non-GBM cell line too, and RP11-1143D24 at 19q12, which, to our knowledge, does not contain any annotated gene. Non-GBMs specific clones are nearly all listed as polymorphic clones in the Genome Variation Database (http://projects.tcag.ca.variation) (Iafrate et al., 2004; Sebat et al., 2004) and were all gained in GBM cell lines too. Gain signals with log 2 ratio>0.3 (Table 5) were shared by both GBMs and non-GBMs for clone RP11-39G12, which, together with the polymorphic clone RP11-79A4, belongs to the 11p-q SRO previously identified by our MA approach (Table 1 ). Array-based CGH in glioma cell lines G Roversi et al Genes residing between the two flanking clones of losses are in italics, and with bolded characters for those mapping within clones. Chromosome 10 clones were not included in the frequency analysis because most of the GBM cell lines analysed lost the entire chromosome.
a Clones falling in SRO (Table 1) 
Discussion
This study reports on an application of high-resolution aCGH to a consistent panel of well-characterized primary glioma cell lines, by means of a 3.5k whole genome plus full-coverage chromosome 19 BAC array. Aiming at the identification of recurrent genomic aberrations involved in glioma genesis and/or progres- Genes residing between the two flanking clones of losses are in italics, and with bolded characters for those mapping within clones. Gray-shaded rows indicate clones of the chromosome 19 full-coverage array. Chromosome 7 clones are not included in Table 5 as most GBM cell lines gained the entire chromosome with values fitting log 2 ratio >0.3. a High-frequency gained clones with both log 2 ratio >0.5 and >0.3. b Clones/genes identified as polymorphic loci in the Genome variation Database (http://projects.tcag.ca.variation).
c Clones falling in SRO (Table 1) . (Schraders et al., 2005) . This approach is considered an important tool to unmask single-copy changes which log 2 ratio values might be underscored particularly in tumors, like gliomas, characterized by high cellular and genetic heterogeneity and ploidy aberrations (Noble and Dietrich, 2004) . In large-scale studies of tumors such as gliomas, for which primary material is hardly ever available for other than diagnostic purposes, primary cell lines have always been considered a good model while studying gliomagenesis (Fischer et al., 1985; Bigner et al., 1987; Rey et al., 1989; Bakir et al., 1998) . Even with the advent of high-resolution techniques, such as aCGH, a remarkable concordance of findings has repeatedly been demonstrated, with only minute differences, between early passage glioma cell lines and corresponding original tumors (Cowell et al., 2004b) . Also, the aCGH data on glioma cell lines presented here confirm the known gross aberrations detected on glioma samples by conventional CGH and LOH analyses, such as þ 7, À10 and À22q, thereby further supporting the reliability of cell lines as research tools in cancer genetics of gliomas.
aCGH data processed by the MA approach facilitated the identification of small genomic regions of copy number changes, all representing novel findings in gliomas, with the exception of the gained region detected in GBMs at 1q32.1, which indeed represents a wellknown amplification target in malignant gliomas (Riemenschneider et al., 2003) . Of particular interest because of their specificity to one of our two glioma groups are losses detected in GBMs at 4p16.1, and in non-GBMs at 3p26.1-p26.3, 4q13.2-q21.1 and 7p15.3-p21.1. In particular, losses mapping at the 3p26.1-p26.3 SRO were shared by 8/15 non-GBM cell lines, and were never observed in GBM cell lines. A correlation between 3p losses and low-grade gliomas has been observed in the past in studies focusing on 3p LOH demonstrating that 40% low-grade gliomas showed 3p LOH, while retention of 3p heterozygosity correlated with high pathological grade: accordingly, patients with 3p LOH had a significantly longer survival time than those without LOH (Kanno et al., 1997) .
In contrast, the remaining SROs we detected at 4p15.31-p15.32, 5q22.2-q23.3, 6p23-p25.3, 11p11.2-q13.2 and 12p13.1-p13.2 are shared by GBMs and non-GBMs, even though some appear to prevail in one of the two groups. Particularly, we observed high deletion frequencies for an SRO mapping to 12p13.1-p13.2, which was found to be lost in three non-GBMs and five GBMs. Single clone analyses also pointed out the involvement of three clones contained in the 12p SRO in at least six GBM lines (60%). 12p has previously been described as site of gain events in gliomas (Weber et al., 1996) , with amplifications targeting the CCND2 gene at 12p13.32 (Buschges et al., 1999) . Our results do not confirm gain/amplification of this locus, but are consistent with the mapping within the 12p SRO of a 12p tumor suppressor locus that has been postulated to be involved in a wide range of hematological malignancies and solid tumors (Montpetit et al., 2002) .
The 11p11.2-q13.2 SRO gained region is observed in three non-GBMs and three GBMs. The RP11-39G12 clone residing within this SRO shows a high gain frequency in non-GBMs and GBMs (both 50%). Several interesting genes map in the affected interval. Among these, the neurite growth-promoting factor MDK has very recently been found amplified in a GBM specimen by aCGH analysis (Cowell et al., 2004b) . DDB2, a DNA repair protein, is involved in the crossresistance of cisplatin-selected cell lines to death ligand-mediated apoptosis (TNF-alpha and Fas-inducing antibody). It functions as a negative regulator of apoptosis because overexpression of DDB2 suppresses TNF signaling-mediated apoptosis (Sun and Chao, 2005) . Therefore, DDB2 may have a pivotal role in regulating efficacy of anticancer drugs like TRAIL (TNF-related apoptosis-inducing ligand), a promising death ligand for glioma treatment (Hawkins, 2004) .
Also the IG20 gene, which appears to have at least seven splice variants, encodes for a protein involved in the TNF-alpha signaling pathway; overexpression of its isoform DENN-SV, the only one expressed in normal brain, enhances cell replication and resistance to TNFalpha, vinblastine, etoposide and g-radiation, supporting the antiapoptotic and cell survival role of DENN-SV (Efimova et al., 2004) .
In addition, aCGH in combination with the MA approach enabled us to further refine known loci involved in glioma progression, such as, for instance, those on chromosome 10. In GBM, loss of chromosome 10 is the most frequently reported genetic event, commonly accounted for by the presence of tumor suppressors on both 10p and 10q. On 10p, the most frequent site of LOH involves band 10p15 (Harada et al., 2000) , whereas for the q arm, known or putative tumor suppressor genes as PTEN (10q23), LGI1 (10q24) and DMBT1 (10q26) are affected in only 30% or less of GBMs, suggesting the presence of additional tumor suppressors genes. More particularly, the 10q25-26 region has been referred to as a target of allelic loss in the majority of GBMs and the WRD11 gene (10q26) has been proposed as a prime positional candidate gene (Chernova et al., 2001) .
The 'MA' data analysis of our GBM cell line panel confirmed both the above-mentioned 'hotspots' on chromosome 10 as deletion targets and pointed out three main peaks of most extreme values at 10p15.3, 10q22.3 and 10q26.13-q26.2. The evidence that these peaks do not include the most known candidate genes led us to assume that other tumor suppressor genes with a critical role in the context of glioma progression might reside within these identified intervals. Interestingly, only the ADARB2 gene, a brain specific deaminase, resides within the 10p15.3 interval. The BBCIP (10q26.6) gene maps within the 10q26.13-q26.2 peak and is among the genes in the interval encompassed by clone RP11-32H11, which is homozygously deleted in the MI-63 cell line. This gene encodes a protein interacting with BRCA2 and CDKN1A (p21), which participates in DNA repair and cell cycle control. It has been shown that the BBCIP beta form inhibits cell cycle progression from G1 to S (Meng et al., 2004) , while its alpha form inhibits brain cancer cell growth, confirming a role as candidate tumor suppressor in brain tumors (Liu et al., 2001) as well as in other tumor types (Meng et al., 2003) .
With regard to chromosome 19, which was interrogated with a full-coverage/tiling path resolution array, one out of the six gliomas with oligodendroglial components and none of the 19 astrocytomas showed deletions at 19q13.3, the well-known LOH area in gliomas, lacking so far any identified tumor suppressor gene (Hartmann et al., 2002) . It has been recently demonstrated by aCGH that 19q LOH in oligodendrogliomas and mixed OA is due to physical loss of genetic material rather than to genetic events as mitotic recombination (Cowell et al., 2004a; Kitange et al., 2005) . Our data raise the question whether or not in astrocytic tumors 19q LOH involves the same region and is caused by the same mechanisms as in tumors containing oligodendroglial components.
We previously reported that the novel serine threonine kinase MARK4 gene at 19q13.32 is duplicated in three GBM cell lines, which were also present in the panel used for this study (MI-4, GBM and MI-7) (Beghini et al., 2003) . By means of the MA algorithm, we found that MARK4 resides within the region of gain in three non-GBMs and in the GBM cell line MI-4. On the contrary, no gains were detected for cell lines GBM and MI-7.
However, the duplication of MARK4 we previously described by FISH analysis was characterized through the use of a much smaller contig containing 10 cosmids, of which LLNL-R31237, only containing MARK4 gene, turned out to be duplicated (Beghini et al., 2003) . On the other hand, the tiling BAC clones array covering entirely MARK4 gene span a region containing genes other than MARK4. As only the minimal MARK4 region is duplicated, this would indeed translate into a small fraction of the BAC clones being gained, leading to a very subtle increase in signal intensity. Consequently, we presume that the lack of detection of MARK4 duplication by aCGH in the above cell lines might be due to the different genomic content of the probes used in these analyses. Interestingly, the MA data analysis highlighted two main gained regions, never before described in gliomas, and mapping to 19p13.11 and 19q13.13-13.2; however, currently no known oncogene has been identified in either one of these two intervals.
Single clone analysis facilitated the identification of very subtle regions not included in the SROs, which, due to their small size, could be directly translated into a limited number of corresponding, and possibly causative genes. Some of these, manifesting as homozygous deletions and found only in GBM cell lines point at tumor suppressor genes including PTEN (10q23), p16 (9p21.3) and ING1 (13q34) (Zhu and Parada, 2002; Collins, 2004; Tallen et al., 2004) , which have previously associated with glioma progression. Others are known as putative tumor suppressor genes involved in other cancer types. For instance, LRP1b (2q22.3) has been postulated to play an important role in the tumorigenesis of lung cancer (Liu et al., 2000) , but is expressed predominantly in the brain (Marschang et al., 2004) . The fact that we reidentified some of these widely acknowledged causative genes in our opinion once more confirms the validity of our approach.
Interestingly, PRDM2, a tumor suppressor gene highly expressed in brain tumors (Muraosa et al., 1996) , represents one of the two genes within the interval of the clone RP11-178M15 at 1p36.21, exclusively lost in 35% of non-GBMs.
Three GBMs showed amplifications at 3q26.3 potentially involving the epithelial-transforming factor (ECT2) proto-oncogene, for which an involvement in brain tumors has never been suggested before.
In our cell lines, we did not detect amplification of the EGFR gene at 7p11.2, which is found in approximately 40% of primary, but rarely in secondary GBMs (Zhu and Parada, 2002; Collins, 2004) . The lack of this finding could be related to the low number in our panel of primary GBMs with an overt de novo diagnosis (five of 10 GBMs), and/or to culture conditions, in line with published data suggesting a selection for amplified EGFR in vivo and a selection against EGFR amplification in vitro (Pandita et al., 2004) also in early passage cultures (Cowell et al., 2004b) .
Further validation focusing on the above-mentioned data will be a necessary step to strengthen the candidate regions and genes within or nearby the clones sorted out from our study, and future research might clarify their potential functional role in glioma genesis and/or progression.
The overall achieved insights and their implications increase our current knowledge about subtle genetic changes in gliomas and may facilitate further identification of novel genetic elements, which are of importance in the onset and/or progression of glial tumors. Definition of the multiplicity of genetic elements involved in gliomagenesis provides us with the necessary background needed for the design of novel molecular tools that can be used for an improved diagnostics/ therapeutic decision-making in gliomas.
Material and methods
Glioma cell lines
Primary cell lines used for this study included one pilocytic astrocytoma (WHO grade I), five astrocytomas of grade II including three mixed OAs, nine anaplastic astrocytomas (WHO grade III) including three mixed AOAs, all classified by us as 'non-GBMs', and 10 gliomas of grade IV (GBMs). Within grade IV, four de novo (primary) GBMs, one secondary (arisen from a previous astrocytoma) GBM, three apparently secondary GBMs (based on tumoral differentiated areas within the specimen, but not attested by previous surgery or anamnesis), one primary giant cell and one apparently secondary giant cell GBM are included.
Primary glioma cell lines were established from biopsy fragments using methods described previously (Magnani et al., 1994) . The GBM (Perego et al., 1994) and MI-4 (Magnani et al., 1994 (Magnani et al., , 1999 (Magnani et al., , 2005 cell lines were used at 33rd and 61st passage, respectively, whereas all other cell lines were used before their 14th passage. All cell lines were maintained in RPMI 1640 medium containing 5% FCS at 371C and 5% CO 2 .
WHO classification, clinical data and cytogenetic analysis of the fresh tumors of origin, when available, are provided in Supplementary Table A. All karyotypes were described according to ISCN 95 guidelines (Mitelman, 1995) .
Additional karyotyping was performed on MI-4, MI-60 (Magnani et al., 1999) , GBM and MI-7 (Magnani et al., 1999) cell lines at the first passages. The first three cell lines presented the same stemline karyotype described primarily, whereas the karyotype of MI-7 revealed a subclone containing 59 chromosomes in addition to the original tumor (46, X, ÀY, þ 7/59,
Array-based CGH aCGH hybridizations were performed on microarrays containing approximately 4300 BAC clones. These BAC clones can be subdivided in approx. 3600 BAC clones that are equally distributed over the entire human genome with an average 800 kb resolution (Schraders et al., 2005) and approx. 700 BAC clones that cover close to the entire chomosome 19 at tiling path resolution. For chromosome 19, a full-coverage set containing approc. 700 chromosome-specific, finger-printed and phage-tested BAC clones was selected from a larger '32k set', which was developed at the British Columbia Cancer Agency Genome Sciences Center, Vancouver, Canada (Krzywinski et al., 2004) . This subset covers chromosome 19 with an average resolution of 100 kb. Preparation of BAC arrays, labeling and hybridizations were performed essentially as described by Vissers et al. (2003) . All hybridizations were performed on the same batch of quality controlled arrays, thereby excluding minor batch-to-batch differences.
Analysis of the microarray images obtained from the BAC hybridizations was performed using the software package GenePix Pro 4.0 (Axon Instruments Inc., Foster City, CA, USA). For each spot, the median pixel intensity minus the median local background for both dyes was used to obtain a genomic copy number ratio. Data normalization was performed in the software package SAS version 8.0 (SAS Institute Inc.) for each array subgrid, by applying Lowess curve fitting with a smoothing factor of 0.3 to predict the log 2 -transformed test-over-reference (T/R) value on the basis of the average logarithmic fluorescent intensities (Cleveland, 1979) . All mapping information regarding clone locations, cytogenetic assignments and gene content were retrieved from the UCSC human genome browser (http://genome.ucsc.edu/, May 2004 freeze).
Statistical analysis
To detect areas of nonoverlapping gained and lost consecutive clones, we applied an algorithm that we have recently described (Schraders et al., 2005) based on extreme values of MAs of normalized log 2 ratios with different window sizes. Mathematical/statistical details underlying this algorithm are available upon request (H.straatman@epib.kun.nl). The most extreme MA in all cell lines was above þ 0.1 or below À0.1, with the exception of two areas, one at 3p and the other at 7p (the most centromeric) (Figure 1 ), both with a mean of À0.09 with a window width of 24 and 27 clones, respectively. The MA algorithm was used in six normal versus normal hybridizations to identify false-positive areas caused by underperformance of individual clones or novel polymorphic regions/large-scale copy number variations (LCVs). All areas of copy number changes identified in cell line samples by MAs with a window width from 2 to 10 were excluded even if present only once in normal versus normal hybridizations, and the same approach was adopted for MAs with a window width from 11 to 30. The only exception was one deleted interval at 4p, where in normal versus normal hybridizations three extreme MAs were detected: the first, with a mean of À0.22 and a window width of eight clones in cell line samples showed higher mean values ranging from À0.35 to À0.57. The other two extreme MAs, with a window width from 11 to 30, showed a mean of À0.14 and À0.17 in normal versus normal hybridizations. Therefore, we included in the analysis only MAs with a window width from 11 to 30 below À0.3 in cell line samples.
For whole chromosome association analysis, a chromosome was scored as gained or lost when: (a) 90% of all clones on the chromosome had a log 2 ratio > or o0, respectively; (b) the median of the log 2 ratio of all clones on that chromosome was > or o0.1 or À0.1, respectively (Hackett et al., 2003) . Samples were hybridized in sex-mismatch hybridization schemes, allowing for a quick objective general assessment of the quality of individual experiments by determination of average normalized T/R values for the sex chromosomes. For this reason, sex chromosomes were excluded for further analysis.
Single clone analysis As a first step, 'suspicious clones', which were defined as clones that have either a standard deviation >0.26 or o0.026 or a z-value (average ratio/standard error) >5 in the normal versus normal hybridizations (references), were discarded. In addition, clones showing a standard deviation d>0.3 over triplicate in the individual experiments were excluded, as well as clones with less than two replicates remaining after this analysis.
Subsequently, copy number changes were scored as gains or losses when the normalized mean log 2 (test/reference) ratio was > þ 0.3 or oÀ0.3, respectively. These boundaries were arbitrarily set by examining the results of the normal versus normal hybridizations and supported by the results of previously published work (Veltman et al., 2003a, b; Vissers et al., 2003) . To detect hotspots of genomic imbalances, we excluded from the analysis clones showing copy number changes in one or more of the six normal versus normal hybridizations. We subsequently established a 'threshold of significance', including in the analysis only informative clones in at least 5/6 normal versus normal, 10/15 'non-GBMs' versus normal and 7/10 'GBMs' versus normal hybridizations. Clones of interest were selected on the basis of the highest frequencies of aberration calculated on informative clones in either 'non-GBM' or GBM specimens.
All information regarding physical maps and genomic content of clones was obtained through the UCSC human genome browser (http://genome.ucsc.edu/, May 2004 freeze), and clones were queried as possible LCVs or CNPs (copy number polymorphisms) at the Genome Variation Database (http://projects.tcag.ca.variation) (Iafrate et al., 2004; Sebat et al., 2004) .
